Literature DB >> 24616367

De-escalation of therapy for pediatric medulloblastoma: trade-offs between quality of life and survival.

Natalie Henrich1, Carlo A Marra, Louise Gastonguay, Donald Mabbott, David Malkin, Chris Fryer, Eric Bouffet, Michael D Taylor, Juliette Hukin, Nadia Scantlebury, Larry Lynd.   

Abstract

BACKGROUND: Treatment intensity for pediatric medulloblastoma may vary depending on the type of medulloblastoma. In some cases, the dose of radiation may be reduced or eliminated. Correspondingly, there may be trade-offs between quality of life and survival. In this study, focus groups were conducted with parents and clinicians to explore their opinions about these trade-offs as well as the alignment/misalignment between parents and clinicians regarding the trade-offs.
METHODS: One hour semi-structured focus groups were conducted with parents of children with medulloblastoma and health care providers who were involved in the care of these children.
RESULTS: Parents and providers showed differences in which factors they believe have the greatest impact on quality of life for children with medulloblastoma and their families. For parents, the most important factor is social functioning and their child's ability to make friends and have a social life. In contrast, providers thought that parents cared most about their child's cognitive functioning and ability to attend and perform in school.
CONCLUSION: Understanding parents' perspectives on quality of life is important in terms of providing support services that target the areas that the parents prioritize. The types of functioning that are most strongly correlated with quality of life from the parents' perspective may be the ones that should be targeted to protect during treatment. Pediatr Blood Cancer 2014;61:1300-1304.
© 2014 Wiley Periodicals, Inc. © 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  brain tumor; medulloblastoma; preferences; quality of life

Mesh:

Year:  2014        PMID: 24616367     DOI: 10.1002/pbc.24990

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  6 in total

Review 1.  Multidisciplinary pediatric brain tumor clinics: the key to successful treatment?

Authors:  Mohamed S Abdel-Baki; Emily Hanzlik; Mark W Kieran
Journal:  CNS Oncol       Date:  2015

2.  Cognitive predictors of social adjustment in pediatric brain tumor survivors treated with photon versus proton radiation therapy.

Authors:  Emily A H Warren; Kimberly P Raghubar; Paul T Cirino; Amanda E Child; Philip J Lupo; David R Grosshans; Arnold C Paulino; M Fatih Okcu; Charles G Minard; M Douglas Ris; Anita Mahajan; Andres Viana; Murali Chintagumpala; Lisa S Kahalley
Journal:  Pediatr Blood Cancer       Date:  2022-03-13       Impact factor: 3.838

3.  DNA methylation profiling is a method of choice for molecular verification of pediatric WNT-activated medulloblastomas.

Authors:  Andrey Korshunov; Felix Sahm; Olga Zheludkova; Andrey Golanov; Damian Stichel; Daniel Schrimpf; Marina Ryzhova; Alexander Potapov; Antje Habel; Jochen Meyer; Peter Lichter; David T W Jones; Andreas von Deimling; Stefan M Pfister; Marcel Kool
Journal:  Neuro Oncol       Date:  2019-02-14       Impact factor: 12.300

Review 4.  Core deficits and quality of survival after childhood medulloblastoma: a review.

Authors:  Mathilde Chevignard; Hugo Câmara-Costa; François Doz; Georges Dellatolas
Journal:  Neurooncol Pract       Date:  2016-08-26

Review 5.  Medulloblastoma in the Molecular Era.

Authors:  Claudia Miranda Kuzan-Fischer; Kyle Juraschka; Michael D Taylor
Journal:  J Korean Neurosurg Soc       Date:  2018-05-01

6.  How do parents and providers trade-off between disability and survival? Preferences in the treatment of pediatric medulloblastoma.

Authors:  Amir Khakban; Tima Mohammadi; Larry D Lynd; Don J Mabbott; Eric Bouffet; Louise Gastonguay; Zafar Zafari; David Malkin; Michael D Taylor; Carlo A Marra
Journal:  Patient Prefer Adherence       Date:  2018-10-10       Impact factor: 2.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.